The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ecolab posts in line first-quarter 2026 earnings as revenue beats expectations and Digital sales surge, while gross margin tightens and guidance is revised.
Arizona State Retirement System cut its holdings in DexCom, Inc. (NASDAQ: DXCM) by 7.4% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Co
DexCom's Q1 results may see strong growth from G7 uptake and CGM demand, but pricing mix and rising investments could weigh on margins.
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

Cwm LLC Sells 91,609 Shares of DexCom, Inc. $DXCM

04:26am, Thursday, 23'rd Apr 2026
Cwm LLC reduced its stake in shares of DexCom, Inc. (NASDAQ: DXCM) by 57.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6
On April 21, 2026, DexCom Inc (DXCM) shares fell 3.1%, bringing the current price to $62.60. The stock has experienced a challenging year, with a 52-week range
Abbott Laboratories and Dexcom are the biggest players in the market for continuous glucose monitoring devices. Abbott has a vast lineup of products beyond that and an overall diversified healthcare b
Chicago Capital LLC lessened its holdings in shares of DexCom, Inc. (NASDAQ: DXCM) by 38.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commissio

Lbp Am Sa Buys 8,296 Shares of DexCom, Inc. $DXCM

04:37am, Saturday, 18'th Apr 2026
Lbp Am Sa lifted its stake in shares of DexCom, Inc. (NASDAQ: DXCM) by 12.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The insti
TransMedics Group's innovative approach could help it capture a larger share of the organ transplant market. Dexcom still has vast untapped opportunities in its niche.
DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and near-term margin risks.

DexCom (DXCM) Upgraded to Buy: Here's Why

01:00pm, Wednesday, 15'th Apr 2026
DexCom (DXCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE